Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and ...

Shares of Structure Therapeutics are soaring Monday after the company reported positive topline data from a weight loss drug ...

Biotech Structure Therapeutics’ (GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped ...

Structure Therapeutics (GPCR) announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small ...

As of Monday, December 08, Structure Therapeutics Inc.’s GPCR share price has surged by 76.80%, which has investors ...

Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...

First identified in 1986, Guanine nucleotide binding protein (G-protein) coupled receptors (GPCRs) are complex proteins found in cell membranes. A notable characteristic of these proteins is that they ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR ...

Structure Therapeutics stock soars 103% as its oral obesity drug aleniglipron shows strong Phase 2b weight-loss results.